The estimated Net Worth of Leslie L Iversen is at least $1.11 Million dollars as of 18 April 2016. Leslie Iversen owns over 33,697 units of Acadia Pharmaceuticals Inc stock worth over $1,113,693 and over the last 20 years Leslie sold ACAD stock worth over $0.
Leslie has made over 8 trades of the Acadia Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Leslie exercised 33,697 units of ACAD stock worth $58,970 on 18 April 2016.
The largest trade Leslie's ever made was exercising 60,000 units of Acadia Pharmaceuticals Inc stock on 2 January 2014 worth over $104,400. On average, Leslie trades about 8,773 units every 46 days since 2004. As of 18 April 2016 Leslie still owns at least 69,824 units of Acadia Pharmaceuticals Inc stock.
You can see the complete history of Leslie Iversen stock trades at the bottom of the page.
Leslie's mailing address filed with the SEC is 3611 VALLEY CENTRE DRIVE, SUITE 300, , SAN DIEGO, CA, 92130.
Over the last 20 years, insiders at Acadia Pharmaceuticals Inc have traded over $21,409,958 worth of Acadia Pharmaceuticals Inc stock and bought 29,279,665 units worth $647,484,672 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B..., and Carl L Gordon. On average, Acadia Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,248,934. The most recent stock trade was executed by Mark C. Schneyer on 16 August 2024, trading 9,733 units of ACAD stock currently worth $148,720.
acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies
Acadia Pharmaceuticals Inc executives and other stock owners filed with the SEC include: